2Kindblom L-G,Meis-Kindblom J,Bümming P,et al.Incidence,prevalence,phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)-a population-based study of 600cases[J].Ann Oncol,2002,13(suppl 5):157.
3Hasegawa T,Matsuno Y,Shimoda T,et al.Gastrointestinal stromal tumor:consistent CD117 immunostaining for diagnosis,and prognostic classification based on tumor size and MIB-1 grade[J].Human Pathol,2002,33(6):669-676.
4DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
5Roberts PJ,Eisenberg B.Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease[J].Eur J Cancer,2002,38(suppl 5):S37-38.
6Heinrich MC,Blanke CD,Druker BJ,et al.Inhibition of KIT tyrosine kinase activity:a novel molecular approach to the treatment of KIT-positive malignancies[J].J Clin Oncol,2002,20(6):1692-1703.
7Mudan SS,Conlon KC,Woodruff JM,et al.Salvage surgery for patients with recurrent gastrointestinal sarcoma:prognostic factors to guide patient selection[J].Cancer,2000,88(1):66 -74.
8De Pas T,Casali PG,Toma S,et al.Gastrointestinal stromal tumors:should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?[J].Oncology,2003,64(1):186-188.
9Joensuu H,Roberts PJ,Sarlomo-Rikala M,et al.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor[J].N Engl J Med,2001,344(14):1052-1056.
10Van Oosterom AT,Judson I,Verweij J,et al.Safety and effi cacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours:a phase I study[J].Lancet,2001,358(9291):1421-1423.
